Abstract
Abstract
Bimatoprost (Lumigan®) is a synthetic prostamide that reduces intraocular pressure (IOP) by increasing the outflow of aqueous humour. In patients with open-angle glaucoma or ocular hypertension, long-term treatment (for up to 48 months) with once-daily bimatoprost 0.03% ophthalmic solution was more effective than timolol twice daily in providing a sustained and stable reduction in IOP. Bimatoprost 0.03% ophthalmic solution demonstrated efficacy similar to, or greater than, the prostaglandin analogues latanoprost and travoprost in reducing IOP and achieving target IOP levels. Switching to bimatoprost was as effective in maintaining diurnal IOP control as switching to a fixed combination of latanoprost/timolol (in patients with IOP levels controlled with a nonfixed combination of latanoprost plus timolol), and similarly, or more, effective in lowering IOP and providing overall diurnal IOP control than switching to a combination of dorzolamide/timolol (in patients with IOP inadequately controlled with other anti-glaucoma agents including timolol). Treatment with bimatoprost was generally well tolerated, with conjunctival hyperaemia (mostly mild), growth of eyelashes and ocular pruritus being commonly reported. Other adverse events included increases in the pigmentation of the iris, perorbital areas and eyelashes.
Pharmacological Properties
Bimatoprost is a synthetic prostamide analogue (structurally related to prostaglandin F2α) that reduces IOP by increasing the outflow of aqueous humour through the trabecular meshwork (pressure-sensitive) and uveoscleral (pressure-insensitive) routes. The IOP-reducing effect of bimatoprost starts ≈4 hours after the first administration of this agent, with the maximum effect being reached within ≈8–12 hours. Bimatoprost provides a constant level of IOP control throughout a 24-hour period.
Penetration of topically administered bimatoprost ophthalmic solution is via the sclera and cornea. After topical administration, systemic absorption of bimatoprost was minimal; peak blood concentrations of bimatoprost were reached rapidly (within 10 minutes) and then declined to below the lower limit of detection within 1.5 hours of administration. There was no accumulation of bimatoprost over time. The elimination half-life of intravenous bimatoprost was ≈45 minutes. Bimatoprost is excreted via the urine and faeces.
Therapeutic Efficacy
Treatment with topical bimatoprost 0.03% once daily for up to 48 months provided sustained reductions in IOP that were significantly greater than those with timolol 0.5% twice daily in patients with glaucoma or ocular hypertension, according to data from two large (n = 596 and 602), 12-month, phase III, randomized, double-blind trials and the extensions of these trials. Over the 48 months of treatment, reductions of IOP from baseline at 0800 and 1000 hours were ≈2–4 mmHg (35–100%) greater with bimatoprost than with timolol. Bimatoprost was more effective than timolol at maintaining overall IOP control throughout the day, and significantly more bimatoprost than timolol recipients achieved target IOP levels.
In several large (n >100), investigator-blind, multicentre trials of up to 6 months’ duration, once-daily bimatoprost 0.03% demonstrated similar, or greater, efficacy than once-daily administration of the prostaglandin analogues latanoprost 0.005% or travoprost 0.004% in lowering IOP and maintaining a stable diurnal IOP in patients with glaucoma or ocular hypertension. Patients (inadequately controlled on latanoprost) who switched to bimatoprost achieved significantly greater reductions in IOP than those remaining on latanoprost or switching to travoprost, according to data from two 3-month, randomized, investigator-blind studies.
Switching to bimatoprost was as effective in maintaining diurnal IOP control as switching to a fixed combination of latanoprost 0.005%/timolol 0.5% in patients with IOP levels controlled with a nonfixed combination of latanoprost plus timolol, according to data from a 3-month, randomized, double-blind trial in patients with glaucoma.
Bimatoprost once daily demonstrated similar or greater efficacy than dorzolamide/timolol twice daily in lowering IOP and in providing overall diurnal control in patients with ocular hypertension and glaucoma, according to data from randomized trials in patients with IOP inadequately controlled with antiglaucoma agents including topical timolol.
Pharmacoeconomic Considerations
Cost-effectiveness analyses of bimatoprost treatment in patients with glaucoma or ocular hypertension conducted from a US healthcare provider perspective demonstrated that bimatoprost was associated with lower costs per treatment success than latanoprost, timolol or timolol/dorzolamide across a range of IOP targets. In all US analyses, bimatoprost was the dominant (more effective and less costly) strategy compared with latanoprost. Data from cost-effectiveness analyses conducted from a European healthcare provider perspective also demonstrated the dominance of bimatoprost over latanoprost for most of the countries assessed. One European analysis also demonstrated that a strategy of first-line timolol therapy with add-on bimatoprost was the dominant strategy compared with latanoprost (as first-line therapy or as add-on therapy to timolol) in the UK, Spain, Germany and Italy. As well as being subject to the usual limitations associated with economic models, other potential limitations associated with these analyses included the use of selected IOP data and the lack of the inclusion of costs associated with conjunctival hyperaemia or other adverse effects of therapy.
Tolerability
Once-daily treatment with bimatoprost 0.03% for up to 48 months was well tolerated in patients with glaucoma or ocular hypertension. The most commonly reported adverse events were conjunctival hyperaemia (mostly mild) and eyelash growth, occurring in 45% and 43% of bimatoprost recipients during the first year of treatment, according to data from two large, phase III trials. Only 3% of recipients of bimatoprost once daily withdrew due to ocular hyperaemia during the first year of treatment. The incidence of both of these adverse events decreased with continued treatment over a 48-month period. Ocular pruritus was another commonly reported adverse event (15%) during the first year of treatment; however, the incidence of new reports of ocular pruritus was minimal during the second year of treatment, with no new cases being reported in subsequent years. Other ocular adverse events, including ocular dryness, visual disturbance and ocular burning, occurred in up to 10% of bimatoprost recipients. The incidence of iris pigmentation reported in bimatoprost recipients in the 12-month, phase III trials was low (1.5%), and there were no new reports of iris pigmentation changes with continued bimatoprost treatment of up to 48 months.
Similar content being viewed by others
References
Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. N Engl J Med 2009 Mar 12; 360(11): 1113–24
National Collaborating Centre for Acute Care. Glaucoma: diagnosis and management of open-angle glaucoma and ocular hypertension [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG85FullGuideline.pdf [Accessed 2009 Aug 24]
McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care 2008 Feb; 14(1 Suppl.): S20–7
Geringer CC, Imami NR. Medical management of glaucoma. Int Ophthalmol Clin 2008 Fall; 48(4): 115–41
European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Editrice Dogma, 2009
American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2005
Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004 Sep; 111(9): 1627–35
Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000 Apr; 9(2): 134–42
Burk RM, Woodward DF. A historical perspective and recent advances in prostamide research and therapeutics. Curr Opin Drug Discov Devel 2007 Jul; 10(4): 413–21
Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf 2008 Nov; 7(6): 801–8
Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 19(3): 231–48
Plosker GL, Keam SJ. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 2006; 24(3): 297–314
Perry CM, McGavin JK, Culy CR, et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003; 20(8): 597–630
Waugh J, Jarvis B. Travoprost. Drugs Aging 2002; 19(6): 465–71; discussion 472–3
European Medicines Agency. Lumigan®: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lumigan/H-391-PI-en.pdf [Accessed 2009 Jul 23]
Allergan Inc. Lumigan® (bimatoprost ophthalmic solution) 0.03%: US prescribing information [online]. Available from URL: http://www.lumigan.com/prescribing_information.aspx [Accessed 2009 Jul 23]
Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S337–45
Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008 Nov; 53Suppl. 1: S107–20
Brubaker RF. Mechanism of action of bimatoprost (Lumigan®). Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S347–51
Paolera MD, Kasahara N, Umbelino CC, et al. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. BMC Ophthalmol 2008 Jun 11; 8: 11
Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 2008 Feb; 153(3): 410–9
Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 2008 Jul; 154(5): 1079–93
Ota T, Aihara M, Narumiya S, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005 Nov; 46(11): 4159–63
Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001 Dec 7; 432(2–3): 211–3
Davies SS, Ju WK, Neufeld AH, et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther 2003 Feb; 19(1): 45–54
Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002 Aug; 47Suppl. 1: S34–40
Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008 Nov; 53Suppl. 1: S69–84
Camras CB, Toris CB, Sjoquist S, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 2004; 111(12): 2193–8
Cantor LB, Hoop J, Wudunn D, et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol 2007 May; 91(5): 629–32
Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects; acrossover study. Ophthalmology 2008 May; 115(5): 790–5.e4
Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001 Jan; 131(1): 19–24
Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004 Sep; 111(9): 1658–62
Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005 Feb; 112(2): 262–6
Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006 Feb; 113(2): 239–46
Walters TR, DuBiner HB, Carpenter SP, et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004 Mar; 49Suppl. 1: S26–35
Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology 2007 Dec; 114(12): 2244–51
Frenkel RE, Frenkel M, Toler A. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 2007; 7: 16
Frenkel RE, Noecker RJ, Craven ER. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%. Curr Med Res Opin 2008 Apr; 24(4): 919–23
Zeitz O, Matthiessen ET, Reuss J. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmology 2005; 5(1): 6
Akarsu C, Yilmaz S, Taner P, et al. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol 2004 Oct; 242(10): 814–8
Alagoz G, Gurel K, Bayer A, et al. A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008; 222(2): 88–95
Sen E, Nalcacioglu P, Yazici A, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 2008 Aug; 17(5): 398–402
Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 2005 Feb; 123(2): 186–92
Arcieri ES, Pierre Filho PT, Wakamatsu TH, et al. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 2008 Feb; 22(2): 179–83
Hatanaka M, Vessani RM, Elias IR, et al. The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 2009 Feb; 25(1): 51–3
Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci 2007 Aug; 48(8): 3677–82
Yeom HY, Hong S, Kim SS, et al. Influence of topical bimatoprost on macular thickness and volume in glaucoma patients with phakic eyes. Can J Ophthalmol 2008 Oct; 43(5): 563–6
Kapur R, Osmanovic S, Toyran S, et al. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005 Nov; 123(11): 1541–6
Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol 2008 Sep; 92(9): 1227–31
Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 2008 Jan 28; 17(1): 36–9
Ozturk F, Ermis SS, Inan UU. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Acta Ophthalmol Scand 2007 Feb; 85(1): 80–3
Sharpe ED, Williams RD, Stewart JA, et al. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J Ocul Pharmacol Ther 2008 Aug; 24(4): 408–13
Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005 May–Jun 30; 15(3): 336–42
Williams RD, Cohen JS, Gross RL, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008 Oct; 92(10): 1387–92
Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily ti-molol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001 Jun; 108(6): 1023–31; discussion 1032
Whitcup SM, Cantor LB, VanDenburgh AM, et al. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 2003 Jan; 87(1): 57–62
Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003 Dec; 110(12): 2362–8
Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006 Nov; 90(11): 1370–3
Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001 May–Jun 30; 18(3): 110–21
Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003 Jan; 135(1): 55–63
Bacharach J, Schenker HI, Caprioli J, et al. Masked, randomized, parallel comparison of IOP-lowering efficacy after switching to bimatoprost 0.03% vs continuing with latanoprost 0.005% [abstract no. 36 plus poster]. American Glaucoma Society 19th Annual Meeting; 2009 Mar 5–8; San Diego (CA)
Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003 May; 135(5): 688–703
Noecker RJ, Earl ML, Mundorf TK, et al. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin 2006 Nov; 22(11): 2175–80
Kammer JA, Katzman B, Ackerman SL, et al. Efficacy and tolerability of bimatoprost versus travoprost in patients previously treated with latanoprost: a 3-month, randomized, masked-evaluator, multicentre study. Br J Ophthalmol. Epub 2009 Sep 1
Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol 2004 Sep; 242(9): 767–70
Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004 Mar; 49Suppl. 1: S45–52
Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002 Oct; 120(10): 1286–93
Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Bimatoprost Study Group. Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S361–8
Simmons ST, Bernstein P, Hollander DA. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Am J Ophthalmol 2008 Sep; 146(3): 473–7
Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006; 24(3): 251–64
Fiscella R, Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging 2006; 23(1): 39–47
Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004 Mar; 49Suppl. 1: S36–44
Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients: a European perspective. Int J Clin Pract 2005 Sep; 59(9): 1011–6
Holmstrom S, Buchholz P, Walt J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006 May; 22(5): 897–905
Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005 Nov; 21(11): 1875–83
Whitson JT, Trattler WB, Matossian C, et al. Ocular surface tolerability of prostaglandin analogues (PGAs) in patients with glaucoma or ocular hypertension [abstract no. 34 plus poster]. American Glaucoma Society 19th Annual Meeting; 2009 Mar 5–8; San Diego (CA)
Sharpe ED, Reynolds AC, Skuta GL, et al. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res 2007 Dec; 32(12): 1037–43
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004 Nov; 82(11): 844–51
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 Oct; 120(10): 1268–79
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 Jun; 120(6): 701–13; discussion 829–30
Lichter PR, Musch DC, Medzihradsky F, et al. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthalmol 1989 Jan 15; 107(1): 11–7
Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998 Oct; 126(4): 487–97
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2001; 130: 429–40
Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126(4): 498–505
Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008 Aug; 126(8): 1030–6
Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002 Nov; 11(11 Suppl.): 16–24
Webers CAB, Beckers HJM, Nuijts RMMA, et al. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 2008; 25(9): 729–59
Curran MP, Orman JS. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging 2009; 26(2): 169–84
Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging 2006; 23(7): 587–97; discussion 598–9
Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 2007 May; 12(2): 313–27
Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005 Jun; 112(6): 953–61
Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009 Mar 14; 25(2): 145–52
Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Experiment Ophthalmol 2007 Sep 31; 35(7): 602–11
Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol 2009; 3: 447–56
Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007 Mar; 23(3): 601–8
Li N, Chen XM, Zhou Y, et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 2006 Nov; 34(8): 755–64
van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005 Jul; 112(7): 1177–85
How AC, Kumar RS, Chen YM, et al. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol 2009 Jun; 93(6): 782–6
Agarwal HC, Gupta V, Sihota R. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. J Ocul Pharmacol Ther 2003 Apr; 19(2): 105–12
Dirks MS, Noecker RJ, Earl M, et al. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther 2006; 23(3): 385–94
Chen MJ, Cheng CY, Chen YC, et al. Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther 2006 Jun; 22(3): 188–93
Stewart WC, Stewart JA, Jenkins JN, et al. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J Glaucoma 2003 Dec; 12(6): 475–9
Pfzier Inc. Xalatan® latanoprost ophthalmic solution: US prescribing information [online]. Available from URL: http://www.pfizer.com/files/products/uspi_xalatan.pdf [Accessed 2009 Aug 26]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Curran, M.P. Bimatoprost. Drugs Aging 26, 1049–1071 (2009). https://doi.org/10.2165/11203210-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11203210-000000000-00000